Advertisement

AAPS PharmSciTech

, 20:36 | Cite as

Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment

  • A. Teixeira
  • V. Vasconcelos
  • M. Teixeira
  • V. Almeida
  • R. Azevedo
  • T. Torres
  • J. M. Sousa Lobo
  • P. C. CostaEmail author
  • I. F. Almeida
Research Article

ABSTRACT

Different types of topical preparations are available as anti-psoriatic medicines, semisolid formulations being the preferred dosage forms for the treatment of body lesions. The mechanical characterization of these semisolid formulations is seldom reported, although mechanical features have been recognized to play an important role in treatment acceptability and adherence. The aim of this study was to characterize the mechanical properties of semisolid topical formulations commercially available for psoriasis treatment. One complementary aim was to evaluate patient satisfaction with topical treatment and discuss the results according to the mechanical features of the dosage form. Eight ointments (O 1–8), five creams (C 1–5), one oleogel (G1), and one excipient (E1—petrolatum) were characterized for textural properties (spreadability and penetration tests) and flow behavior. Power law model was fitted to the results. A questionnaire for the assessment of satisfaction with topical medicines used for psoriasis treatment over 6 months was developed and applied to 79 psoriasis patients. All the tested formulations presented a shear-thinning behavior with power law indexes (n) lower than 1. Ointments were distinct from the other dosage forms, since they presented higher consistency coefficients (K), firmness, and adhesiveness and this was evidenced by hierarchical cluster analysis, which identified two clusters based on the mechanical properties. Cluster 1 included the ointments and petrolatum and the cluster 2 enclosed the creams and the gel. The clusters were associated with several attributes classified by patients as analyzed with Fisher’s exact test. In all cases, higher satisfaction was observed for cluster 2. The knowledge obtained regarding the influence of the dosage form on the degree of satisfaction with the treatment could be helpful in supporting the selection of the dosage form in clinical practice and thus improve treatment adherence and clinical outcomes. The differences observed between the mechanical properties of the formulations studied may be also relevant to the industry, as guidance to the development of new medicines.

KEY WORDS

psoriasis topical medicines rheological analysis texture patient preference 

Notes

Acknowledgements

This work was supported by Cooperativa de Ensino Superior Universitário (CESPU) under the Grants “POSOL_DERM_CESPU_2016” and “PHARM4ADHER_CESPU_2017.”

Supplementary material

12249_2018_1246_MOESM1_ESM.docx (702 kb)
ESM 1 (DOCX 702 kb)

References

  1. 1.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.CrossRefGoogle Scholar
  2. 2.
    Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J Dermatol Treat. 2017;28(5):374–83.Google Scholar
  3. 3.
    Al Raddadi AA, Fatani MI, Shaikh YH, Thaci D, Al Reshaid AA, Al-Eisa AM, et al. Adopted guidelines of care for the topical management of psoriasis from American and German guidelines. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2011;15(1):5–13.CrossRefGoogle Scholar
  4. 4.
    Menter A, Gold LS, Bukhalo M, Grekin S, Kempers S, Boyce BM, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013;12(1):92–8.PubMedGoogle Scholar
  5. 5.
    Del Rosso JQ. Calcipotriene-betamethasone dipropionate topical suspension in the management of psoriasis: a status report on available data with an overview of practical clinical application. Cutis. 2014;94(3):127–34.PubMedGoogle Scholar
  6. 6.
    Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR. Calcipotriene 0.005%–betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis. 2014;94(6):304–9.PubMedGoogle Scholar
  7. 7.
    Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol. 2005;19:2–6.CrossRefGoogle Scholar
  8. 8.
    Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: 4- and 12-week interim results from the PRO-long study. J Eur Acad Dermatol Venereol. 2014;28:1723–31.CrossRefGoogle Scholar
  9. 9.
    Puig L, Carrascosa JM, Belinchon I, Fernandez-Redondo V, Carretero G, Ruiz-Carrascosa JC, et al. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr. 2013;104(6):488–96.CrossRefGoogle Scholar
  10. 10.
    Marty J, Lafforgue C, Grossiord J, Soto P. Rheological properties of three different vitamin D ointments and their clinical perception by patients with mild to moderate psoriasis. Journal European academy of dermatology and Venereology. 2005;19(suppl. 3):7–10.CrossRefGoogle Scholar
  11. 11.
    Oliveira SM, Almeida IF, Costa PC, Barrias CC, Ferreira MRP, Bahia MF, et al. Characterization of polymeric solutions as injectable vehicles for hydroxyapatite microspheres. AAPS PharmSciTech. 2010;11(2):852–8.CrossRefGoogle Scholar
  12. 12.
    Jones DS, Lawlor MS, Woolfson AD. Examination of the flow rheological and textural properties of polymer gels composed of poly(methylvinylether-co-maleic anhydride) and poly(vinylpyrrolidone): rheological and mathematical interpretation of textural parameters. J Pharm Sci. 2002;91(9):2090–101.CrossRefGoogle Scholar
  13. 13.
    Almeida IF, Bahia MF. Evaluation of the physical stability of two oleogels. Int J Pharm. 2006;327(1–2):73–7.CrossRefGoogle Scholar
  14. 14.
    Finch T, Shim TN, Roberts L, Johnson O. Treatment satisfaction among patients with moderate-to-severe psoriasis. The Journal of Clinical and Aesthetic Dermatology. 2015;8(4):26–30.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Bourne MC. Texture profile analysis. Food Technol. 1978;32(2):62–72.Google Scholar
  16. 16.
    Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014;94(1):46–53.PubMedGoogle Scholar
  17. 17.
    Europe Co. European pharmacopoeia. 6th ed. Strasbourg: Council of Europe; 2001.Google Scholar
  18. 18.
    Park EK, Song KW. Rheological evaluation of petroleum jelly as a base material in ointment and cream formulations: steady shear flow behavior. Arch Pharm Res. 2010;33(1):141–50.CrossRefGoogle Scholar
  19. 19.
    Thurston GB, Martin A. Rheology of pharmaceutical systems: oscillatory and steady shear of non-Newtonian viscoelastic liquids. J Pharm Sci. 1978;67(11):1499–506.CrossRefGoogle Scholar
  20. 20.
    European Pharmacopeia. European directorate for the quality of medicines. 9th ed. 2016.Google Scholar
  21. 21.
    Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Goerdt S, Peitsch WK. Treatment satisfaction of patients with psoriasis. Acta Derm Venereol. 2015;95(5):572–8.CrossRefGoogle Scholar
  22. 22.
    Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.CrossRefGoogle Scholar
  23. 23.
    Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31:1271–84.CrossRefGoogle Scholar
  24. 24.
    Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:61–7.CrossRefGoogle Scholar
  25. 25.
    Zschocke I, Mrowietz U, Karakasili E, Reich K. Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28:4–9.CrossRefGoogle Scholar
  26. 26.
    ASTM E1490 - 11 Standard Guide for Two Sensory Descriptive Analysis Approaches for Skin Creams and Lotions. 2011.Google Scholar
  27. 27.
    Iversen L, Jakobsen HB. Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol Ther. 2016;6(2):273–85.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • A. Teixeira
    • 1
    • 2
  • V. Vasconcelos
    • 1
  • M. Teixeira
    • 1
  • V. Almeida
    • 1
    • 2
  • R. Azevedo
    • 1
  • T. Torres
    • 3
  • J. M. Sousa Lobo
    • 2
  • P. C. Costa
    • 2
    Email author
  • I. F. Almeida
    • 2
  1. 1.CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da SaúdeGandraPortugal
  2. 2.UCIBIO, REQUIMTE, Laboratório de Tecnologia Farmacêutica, Departamento de Ciências do MedicamentoFaculdade de Farmácia da Universidade do PortoPortoPortugal
  3. 3.Serviço de Dermatologia, Centro Hospitalar do PortoHospital de Santo AntónioPortoPortugal

Personalised recommendations